|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FAM221A |
Gene summary for FAM221A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FAM221A | Gene ID | 340277 |
| Gene name | family with sequence similarity 221 member A | |
| Gene Alias | C7orf46 | |
| Cytomap | 7p15.3 | |
| Gene Type | protein-coding | GO ID | GO:0003674 | UniProtAcc | A0A024RA57 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 340277 | FAM221A | LZE5T | Human | Esophagus | ESCC | 7.61e-04 | 2.90e-01 | 0.0514 |
| 340277 | FAM221A | LZE7T | Human | Esophagus | ESCC | 1.44e-05 | 3.89e-01 | 0.0667 |
| 340277 | FAM221A | LZE20T | Human | Esophagus | ESCC | 3.86e-04 | 6.98e-02 | 0.0662 |
| 340277 | FAM221A | LZE24T | Human | Esophagus | ESCC | 7.58e-17 | 5.72e-01 | 0.0596 |
| 340277 | FAM221A | P1T-E | Human | Esophagus | ESCC | 2.47e-04 | 1.31e-01 | 0.0875 |
| 340277 | FAM221A | P2T-E | Human | Esophagus | ESCC | 1.76e-07 | 6.95e-02 | 0.1177 |
| 340277 | FAM221A | P4T-E | Human | Esophagus | ESCC | 9.51e-11 | 2.19e-01 | 0.1323 |
| 340277 | FAM221A | P8T-E | Human | Esophagus | ESCC | 8.16e-23 | 4.25e-01 | 0.0889 |
| 340277 | FAM221A | P9T-E | Human | Esophagus | ESCC | 1.17e-02 | 6.19e-04 | 0.1131 |
| 340277 | FAM221A | P10T-E | Human | Esophagus | ESCC | 7.41e-11 | 2.25e-01 | 0.116 |
| 340277 | FAM221A | P11T-E | Human | Esophagus | ESCC | 3.79e-03 | 2.08e-01 | 0.1426 |
| 340277 | FAM221A | P12T-E | Human | Esophagus | ESCC | 2.68e-02 | -9.17e-03 | 0.1122 |
| 340277 | FAM221A | P15T-E | Human | Esophagus | ESCC | 3.85e-06 | 2.68e-02 | 0.1149 |
| 340277 | FAM221A | P16T-E | Human | Esophagus | ESCC | 7.37e-04 | -7.78e-03 | 0.1153 |
| 340277 | FAM221A | P20T-E | Human | Esophagus | ESCC | 1.75e-08 | 8.04e-02 | 0.1124 |
| 340277 | FAM221A | P22T-E | Human | Esophagus | ESCC | 1.47e-02 | 8.41e-03 | 0.1236 |
| 340277 | FAM221A | P23T-E | Human | Esophagus | ESCC | 4.83e-12 | 1.56e-01 | 0.108 |
| 340277 | FAM221A | P24T-E | Human | Esophagus | ESCC | 2.50e-04 | 3.02e-02 | 0.1287 |
| 340277 | FAM221A | P26T-E | Human | Esophagus | ESCC | 2.23e-08 | 1.03e-01 | 0.1276 |
| 340277 | FAM221A | P27T-E | Human | Esophagus | ESCC | 4.47e-16 | 3.18e-01 | 0.1055 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FAM221A | SNV | Missense_Mutation | c.682N>T | p.Asp228Tyr | p.D228Y | A4D161 | protein_coding | deleterious(0) | possibly_damaging(0.795) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| FAM221A | deletion | Frame_Shift_Del | novel | c.582delN | p.Thr195LeufsTer13 | p.T195Lfs*13 | A4D161 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| FAM221A | SNV | Missense_Mutation | rs777343625 | c.146G>A | p.Arg49His | p.R49H | A4D161 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| FAM221A | SNV | Missense_Mutation | novel | c.856N>G | p.Lys286Glu | p.K286E | A4D161 | protein_coding | deleterious_low_confidence(0.04) | benign(0.006) | TCGA-VS-A9UD-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
| FAM221A | SNV | Missense_Mutation | c.128G>T | p.Arg43Ile | p.R43I | A4D161 | protein_coding | deleterious(0.01) | benign(0.096) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| FAM221A | SNV | Missense_Mutation | c.140N>A | p.Pro47His | p.P47H | A4D161 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
| FAM221A | SNV | Missense_Mutation | novel | c.286N>T | p.Pro96Ser | p.P96S | A4D161 | protein_coding | deleterious(0) | possibly_damaging(0.833) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| FAM221A | SNV | Missense_Mutation | rs777343625 | c.146N>A | p.Arg49His | p.R49H | A4D161 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| FAM221A | SNV | Missense_Mutation | novel | c.95N>C | p.Leu32Pro | p.L32P | A4D161 | protein_coding | deleterious(0.04) | benign(0.258) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| FAM221A | SNV | Missense_Mutation | novel | c.812N>A | p.Arg271Lys | p.R271K | A4D161 | protein_coding | tolerated(0.33) | benign(0.05) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |